Live Breaking News & Updates on Abilify Maintena

Stay updated with breaking news from Abilify maintena. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Abilify Asimtufii Approved for Schizophrenia, Bipolar I Disorder

The FDA has approved Abilify Asimtufii (aripiprazole), administered every 2 months, for schizophrenia and bipolar I disorder. ....

Abilify Maintena , Abilify Asimtufii , Drug Administration ,

FDA Approves Aripiprazole as First Once-Every-2-Months Long-Acting Injectable for Schizophrenia, Bipolar I Disorder

The formulation in 960 mg and 720 mg prefilled syringes delivers sustained plasma concentrations comparable to those demonstrated in studies with Abilify Maintena. ....

Abilify Asimtufii , Abilify Maintena , Johan Luthman , Olivier Le Moal ,

H. Lundbeck A/S (OTCMKTS:HLUYY) Stock Price Down 0%

H. Lundbeck A/S (OTCMKTS:HLUYY – Get Rating) shares dropped 0% during trading on Friday . The stock traded as low as $22.00 and last traded at $22.00. Approximately 7,500 shares changed hands during mid-day trading, an increase of 327% from the average daily volume of 1,758 shares. The stock had previously closed at $22.01. Analyst […] ....

United States , Brintellix Trintellix , Abilify Maintena , Rexulti Rxulti , Jpmorgan Chase Co , Get Rating , North America , H Lundbecka S , Otcmkts Hluyy ,